Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Decreased expression levels of PIWIL1, PIWIL2, and PIWIL4 are associated with worse survival in renal cell carcinoma patients.

Iliev R, Stanik M, Fedorko M, Poprach A, Vychytilova-Faltejskova P, Slaba K, Svoboda M, Fabian P, Pacik D, Dolezel J, Slaby O.

Onco Targets Ther. 2016 Jan 8;9:217-22. doi: 10.2147/OTT.S91295. eCollection 2016.

2.

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.

Buchler T, Bortlicek Z, Poprach A, Pavlik T, Veskrnova V, Honzirkova M, Zemanova M, Fiala O, Kubackova K, Slaby O, Svoboda M, Vyzula R, Dusek L, Melichar B; Czech Renal Cancer Cooperative Group.

Eur Urol. 2015 Dec 30. pii: S0302-2838(15)01240-3. doi: 10.1016/j.eururo.2015.12.031. [Epub ahead of print]

PMID:
26746623
3.

[A Case of Delayed Dia-gnosis of Acral Lentiginous Melanoma].

Gottvaldová M, Jedličková H, Poprach A, Vašků V.

Klin Onkol. 2015;28(6):439-43. Czech.

PMID:
26673994
4.

[Side effects of Modern Immunotherapy and How to Solve Them in the Clinics].

Lakomý R, Poprach A.

Klin Onkol. 2015;28 Suppl 4:4S103-14. Review. Czech.

PMID:
26647898
5.

Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.

Krajsová I, Arenberger P, Lakomý R, Kubala E, Březinová I, Poprach A, Šťastný M, Mužík J, Melichar B.

Anticancer Res. 2015 Nov;35(11):6303-10.

PMID:
26504067
6.

High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.

Fiala O, Pesek M, Finek J, Topolcan O, Racek J, Minarik M, Benesova L, Bortlicek Z, Poprach A, Buchler T.

Tumour Biol. 2015 Dec;36(12):9215-22. doi: 10.1007/s13277-015-3660-3. Epub 2015 Jun 19.

PMID:
26088452
7.

miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.

Merhautova J, Hezova R, Poprach A, Kovarikova A, Radova L, Svoboda M, Vyzula R, Demlova R, Slaby O.

Biomed Res Int. 2015;2015:941980. doi: 10.1155/2015/941980. Epub 2015 May 3.

8.

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.

Kubackova K, Melichar B, Bortlicek Z, Pavlik T, Poprach A, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Prausova J, Buchler T; Czech Renal Cancer Cooperative Group.

Target Oncol. 2015 Dec;10(4):557-63. doi: 10.1007/s11523-015-0366-9.

PMID:
25903462
9.

Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency.

Poprach A, Bortlicek Z, Melichar B, Lakomy R, Svoboda M, Kiss I, Zemanova M, Fiala O, Kubackova K, Coufal O, Pavlik T, Dusek L, Vyzula R, Buchler T.

Eur J Cancer. 2015 Mar;51(4):507-13. doi: 10.1016/j.ejca.2014.12.010. Epub 2015 Jan 7.

PMID:
25577735
10.

A simple model to assess the probability of invasion in ductal carcinoma in situ of the breast diagnosed by needle biopsy.

Coufal O, Selingerová I, Vrtělová P, Krsička P, Gabrielová L, Fabian P, Stískalová K, Schneiderová M, Poprach A, Justan I.

Biomed Res Int. 2014;2014:480840. doi: 10.1155/2014/480840. Epub 2014 Jul 8.

11.

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.

Buchler T, Bortlicek Z, Poprach A, Kubackova K, Kiss I, Zemanova M, Fiala O, Dusek L, Vyzula R, Melichar B; Czech Renal Cancer Cooperative Group.

Urol Oncol. 2014 Jul;32(5):569-75. doi: 10.1016/j.urolonc.2013.12.007. Epub 2014 Mar 12.

PMID:
24629497
12.

Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.

Kiss I, Bortlicek Z, Melichar B, Poprach A, Halamkova J, Vyzula R, Dusek L, Buchler T.

Anticancer Res. 2014 Feb;34(2):949-54.

PMID:
24511038
13.

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.

Poprach A, Pavlik T, Melichar B, Kubackova K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Buchler T; Czech Renal Cancer Cooperative Group.

Urol Oncol. 2014 May;32(4):488-95. doi: 10.1016/j.urolonc.2013.09.011. Epub 2013 Dec 8.

PMID:
24321257
14.

[Epidemiological and clinico-pathological characteristics of patients with renal carcinoma: a single institution analysis of 544 cases].

Poprach A, Lakomý R, Selingerová I, Dolečková B, Bílek O, Slabý O, Héžová R, Fabian P, Staník M, Pavlík T, Bortlíček Z, Mlčochová H, Tkáč D, Vyzula R, Kiss I, Kocák I, Kocáková I, Svoboda M.

Klin Onkol. 2013;26(2):114-23. Czech.

PMID:
23718670
15.

[Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].

Büchler T, Finek J, Hájek J, Kocák I, Kubácková K, Lakomý R, Melichar B, Petruzelka L, Poprach A, Siffnerová M, Tomásek J, Vyzula R, Zemanová M; Cezkou Kooperativní Skupinu pro Metastický Renální Karcinom.

Klin Onkol. 2013;26(1):55-7. Czech. No abstract available.

PMID:
23607143
16.

MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.

Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, Radova L, Svoboda M, Dolezel J, Vyzula R, Slaby O.

Tumour Biol. 2013 Feb;34(1):481-91. doi: 10.1007/s13277-012-0573-2. Epub 2012 Nov 13.

PMID:
23150176
17.

[The RENIS clinical registry].

Poprach A, Büchler T, Bortlíček Z, Dušek L, Vyzula R.

Klin Onkol. 2012;25(4):299-301. Czech. No abstract available.

PMID:
22920173
18.

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.

Buchler T, Pavlik T, Bortlicek Z, Poprach A, Vyzula R, Abrahamova J, Melichar B.

Med Oncol. 2012 Dec;29(5):3321-4. doi: 10.1007/s12032-012-0293-x. Epub 2012 Jun 30.

PMID:
22752573
19.

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.

Poprach A, Bortlíček Z, Büchler T, Melichar B, Lakomý R, Vyzula R, Brabec P, Svoboda M, Dušek L, Gregor J.

Med Oncol. 2012 Dec;29(5):3314-20. doi: 10.1007/s12032-012-0286-9. Epub 2012 Jun 30.

PMID:
22752571
20.

[Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].

Svoboda M, Navrátil J, Fabian P, Palácová M, Gombošová J, Slámová L, Princ D, Syptáková B, Kudláček A, Bílek O, Pospíšil P, Kazda T, Grell P, Poprach A, Selingerová I, Nenutil R, Juráček J, Héžová R, Slabý O, Vyzula R.

Klin Onkol. 2012;25(3):188-98. Czech. Erratum in: Klin Onkol. 2013;26(2):139.

PMID:
22724568
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk